Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab vs placebo in nonrelapsing secondary progressive multiple sclerosis
2023-504359-29-01Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Frexalimab with Placebo (2 arms). Primary endpoint: Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months. Planned start Dec 2024; status: authorised.
02
Drugs
frexalimab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2023-504359-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504359-29-01.